Steven Oh
Director, Office of Cellular Therapy and Human Tissue, Office of Therapeutic Products, CBER, US Food & Drug Administration
Steven Oh is listed as Director, Office of Cellular Therapy and Human Tissue, Office of Therapeutic Products, CBER, US Food & Drug Administration. Steven is scheduled to speak at Advanced Therapies Week 2027 on 20 January 2027.
Compiled from published conference agendas; not yet confirmed by Steven. Is this you? Claim this profile.
About
Dr. Steven Oh is Director of the Office of Cellular Therapy and Human Tissue (OCTHT) at FDA's Center for Biologics Evaluation and Research (CBER), where he leads product quality reviews, policy development, and regulatory science research spanning cellular therapy, tissue engineering, and xenotransplantation. He also directs CBER's regulatory bioinformatics and AI group. With nearly two decades of progressive FDA leadership, Dr. Oh's expertise spans regenerative medicine, genome editing, individualized therapies, and global regulatory convergence. He previously served on the faculty at Tufts University School of Medicine and trained at the University of Michigan, Johns Hopkins, and MIT.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Keynote Regulatory Roundtable - perspectives on key areas of importance to the cell & gene therapy industry Speaker · 20 January 2027
- Plenary: Plotting a course to sustainable future success for the cell & gene therapy industry Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Steven at events on B2DB.
- Yoshiaki Maruyama Director, Office of Cellular and Tissue-based Products · Pharmaceuticals and Medical Devices Agency (PMDA), Japan 2 shared sessions
- Sven Kili Partner · Saisei Ventures 1 shared session
- Cédric Cleyrat Executive Director, Head of Cell Therapy BioEngineering & Technology Innovation · Bristol Myers Squibb 1 shared session
- Gina Jiang Managing Director · Hong Kong Institute of Biotechnology 1 shared session
- Nelly Viseux VP Cell Therapies Development, Manufacturing Supply & Quality · Regeneron Pharmaceuticals 1 shared session
- Peter He Co-Founder & Chief Scientific Officer · OriCell Therapeutics 1 shared session
- Samar Mohanty President & CSO · Nanoscope Therapeutics 1 shared session